Results 31 to 40 of about 2,450,636 (325)

Risk factors for high anti-HHV-8 antibody titers (≥1:51,200) in black, HIV-1 negative South African cancer patients: a case control study [PDF]

, 2003
Background: Infection with human herpesvirus 8 (HHV-8) is the necessary causal agent in the development of Kaposi's sarcoma (KS). Infection with HIV-1, male gender and older age all increase risk for KS.
BM Friedman, C Boshoff, C Boshoff, D Serraino, D Whitby, DH Kedes, Dimitra Bourboulia, EP Zorrilla, F Sitas, F Vitale, Freddy Sitas, G de-The, G de-The, G Rezza, GR Simpson, H Renwick, J Iscovich, J Ziegler, Janet M Wojcicki, JJ Goedert, JL Ziegler, JL Ziegler, KA Staskus, L Rainbow, Lara Stein, LD Baker, M Dedicoat, Margaret I Urban, Martin Hale, Moosa Patel, P Cook-Mozaffari, P Kellam, Paul Ruff, PS Moore, R Greenblatt, R Newton, R Newton, R Tedeschi, Ranjan Sur, RJ Biggar, Rob Newton, RP Stowe, S Lemeshow, S Plancoulaine, SJ Gao, STATA, Statistics South Africa, TH Bothwell, TH Bothwell, VR Gordeuk, Y Chang, Z Grossman   +51 more
core   +2 more sources

Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses.

PLoS Pathogens, 2016
Emerging data support a role for antibody Fc-mediated antiviral activity in vaccine efficacy and in the control of HIV-1 replication by broadly neutralizing antibodies.
Matthew Zirui Tay, Pinghuang Liu, LaTonya D Williams, Michael D McRaven, Sheetal Sawant, Thaddeus C Gurley, Thomas T Xu, S Moses Dennison, Hua-Xin Liao, Agnès-Laurence Chenine, S Munir Alam, M Anthony Moody, Thomas J Hope, Barton F Haynes, Georgia D Tomaras   +14 more
doaj   +1 more source

Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. [PDF]

PLoS Medicine, 2009
The antibody response to HIV-1 does not appear in the plasma until approximately 2-5 weeks after transmission, and neutralizing antibodies to autologous HIV-1 generally do not become detectable until 12 weeks or more after transmission.
Marc C Levesque, M Anthony Moody, Kwan-Ki Hwang, Dawn J Marshall, John F Whitesides, Joshua D Amos, Thaddeus C Gurley, Sallie Allgood, Benjamin B Haynes, Nathan A Vandergrift, Steven Plonk, Daniel C Parker, Myron S Cohen, Georgia D Tomaras, Paul A Goepfert, George M Shaw, Jörn E Schmitz, Joseph J Eron, Nicholas J Shaheen, Charles B Hicks, Hua-Xin Liao, Martin Markowitz, Garnett Kelsoe, David M Margolis, Barton F Haynes   +24 more
doaj   +1 more source

Semen IgM, IgG1, and IgG3 Differentially Associate With Pro-Inflammatory Cytokines in HIV-Infected Men

Frontiers in Immunology, 2019
Genital inflammation significantly increases the risk for HIV infection. The seminal environment is enriched in pro-inflammatory cytokines and chemokines.
Thevani Pillay, Parveen Sobia, Abraham Jacobus Olivier, Kapil Narain, Lenine J. P. Liebenberg, Lenine J. P. Liebenberg, Sinaye Ngcapu, Sinaye Ngcapu, Mesuli Mhlongo, Jo-Ann S. Passmore, Jo-Ann S. Passmore, Jo-Ann S. Passmore, Jo-Ann S. Passmore, Cheryl Baxter, Derseree Archary, Derseree Archary   +15 more
doaj   +1 more source

9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles. [PDF]

PLoS ONE, 2013
Potent HIV-1 specific broadly neutralizing antibodies (BNA) are uncommon in HIV infected individuals, and have proven hard to elicit by vaccination. Several, isolated monoclonal BNA are polyreactive and also recognize self-antigens, suggesting a breach ...
Danielle C Alcéna, James J Kobie, Denise A Kaminski, Alexander F Rosenberg, Jonelle L Mattiacio, Matthew Brewer, Stephen Dewhurst, Carrie Dykes, Xia Jin, Michael C Keefer, Ignacio Sanz   +10 more
doaj   +1 more source

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. [PDF]

PLoS ONE, 2015
UNLABELLED:Vaccine-induced HIV antibodies were evaluated in serum samples collected from healthy Tanzanian volunteers participating in a phase I/II placebo-controlled double blind trial using multi-clade, multigene HIV-DNA priming and recombinant ...
Agricola Joachim, Charlotta Nilsson, Said Aboud, Muhammad Bakari, Eligius F Lyamuya, Merlin L Robb, Mary A Marovich, Patricia Earl, Bernard Moss, Christina Ochsenbauer, Britta Wahren, Fred Mhalu, Eric Sandström, Gunnel Biberfeld, Guido Ferrari, Victoria R Polonis   +15 more
doaj   +1 more source

Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals. [PDF]

, 2017
Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and leads for the design of a vaccine that can protect human beings against various clades of Human Immunodeficiency Virus (HIV).
Ashokkumar, Manickam, Babu, Hemalatha, Buddolla, Viswanath, Chandrasekaran, Padmapriyadarsini, Cheedarla, Narayanaiah, Hanna, Luke Elizabeth, Kailasam, Nandagopal, Precilla, K Lucia, Ramanathan, VD, Sundaramurthi, Jagadish Chandrabose, Swaminathan, Soumya, Vaniambadi, S Kalyanaraman, Vijayan, KK Vidya   +12 more
core   +3 more sources

Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals [PDF]

, 2014
Background The MPER region of the HIV-1 envelope glycoprotein gp41 is targeted by broadly neutralizing antibodies. However, the localization of this epitope in a hydrophobic environment seems to hamper the elicitation of these antibodies in HIV infected
Blanco, Julià, Carrillo, Jorge, Clotet, Bonaventura, Curriu, Marta, García, Elisabet, Marfil, Sílvia, Molinos-Albert, Luis M., Rodríguez de la Concepción, Maria L.   +7 more
core   +2 more sources

The human anti-HIV antibodies 2F5, 2G12, and PG9 differ in their susceptibility to proteolytic degradation: Down-regulation of endogenous serine and cysteine proteinase activities could improve antibody production in plant-based expression platforms

Biotechnology Journal, 2014
The tobacco-related species Nicotiana benthamiana has recently emerged as a promising host for the manufacturing of protein therapeutics. However, the production of recombinant proteins in N.
M. Niemer, Ulrich Mehofer, J. A. Torres Acosta, Maria Verdianz, T. Henkel, A. Loos, R. Strasser, D. Maresch, T. Rademacher, H. Steinkellner, L. Mach   +10 more
semanticscholar   +1 more source

Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins

EBioMedicine, 2016
Human immunodeficiency virus type 1 (HIV-1) has evolved a sophisticated strategy to conceal conserved epitopes of its envelope glycoproteins (Env) recognized by antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. These antibodies, which
Jonathan Richard, Beatriz Pacheco, Neelakshi Gohain, Maxime Veillette, Shilei Ding, Nirmin Alsahafi, William D. Tolbert, Jérémie Prévost, Jean-Philippe Chapleau, Mathieu Coutu, Manxue Jia, Nathalie Brassard, Jongwoo Park, Joel R. Courter, Bruno Melillo, Loïc Martin, Cécile Tremblay, Beatrice H. Hahn, Daniel E. Kaufmann, Xueling Wu, Amos B. Smith III, Joseph Sodroski, Marzena Pazgier, Andrés Finzi   +23 more
doaj   +1 more source